Sales conference

Gold Standard Diagnostics visits Bremerhaven

On 12 May 2023, we received a visit from a team from our exclusive sales partner Gold Standard Diagnostik at our offices in Bremerhaven.
We are proud to continue on the path we embarked on in November 2022 with this well-connected and established partner across Europe and look forward to continuing our intensive and fruitful collaboration.

Gruppenbild am Hafen
From left to right: Bianca Imbusch, Frank Dorsch, Sabrina Helms, Dr Markus Rahaus, Dr Markus Klemke, Marcello Salio, MBA, Dr Nina Winter, Eva Zafra, Dr Eckhard Schwenner, Stefani Jedon, Stefano Ronchetti, PhD, Dr Anida Mesihovic
About mir|detect

The mir|detect GmbH based in Bremerhaven, Germany, develops and produces nucleic acid-based in-vitro diagnostics for the early detection and aftercare of cancer. The CE-IVD-certified flagship product, the M371-Testenables the high-precision diagnosis and monitoring of testicular germ cell tumours. Based on the patented and innovative panta|Q® Technology mir|detect is working on a new generation of liquid biopsy tests.

Contact:
mir|detect GmbH
Fischkai 1 - 27572 Bremerhaven
E-Mail: info@mirdetect.deWeb: www.mirdetect.de

Close
Home page
Functionality
About us
Sales partner
Downloads
Contact us

Copyright by me|detect & 21HAVN